
Opinion|Videos|May 22, 2026
Choosing Between Continuous and Fixed Dosing Options in Frontline
Author(s)Andrew H. Lipsky, MD
Six-year data show zanubrutinib remains well tolerated, with rare atrial fibrillation, low bleeding, and no new safety concerns.
Advertisement
Episodes in this series

In the SEQUOIA trial, the BTK inhibitor zanubrutinib was delivered as a continuous dose in frontline chronic lymphocytic leukemia. Andrew H. Lipsky,MD, discusses the potential lifestyle benefits for patients of a continuous dosing approach. He describes BTK monotherapy as the “most simplistic option that we can offer our patients in frontline CLL” at the current time.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
2
Ateganosine Plus Cemiplimab Shows 90.5% Disease Control in Pretreated NSCLC
3
CMS Proposes Cut to 340B Drug Payments in 2027 Outpatient Rule
4
FDA Accepts NDA for Varegacestat in Desmoid Tumors
5










































